吉西他滨联合顺铂治疗耐药转移性乳腺癌的临床观察  

Gemcitabine plus cisplatin for the treatment of drug-resistant metastatic breast cancer

作　　者：娄广媛[1] 李铁[1] 陈金麟[1] 古翠萍[1] 洪丹[1] 张沂平[1] 

机构地区：[1]浙江省肿瘤医院化疗中心,浙江杭州310022

出　　处：《中华肿瘤防治杂志》2009年第3期229-231,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：观察吉西他滨联合顺铂(DDP)方案治疗蒽环类和(或)紫杉类耐药转移性乳腺癌的疗效和不良反应。采用吉西他滨联合DDP方案治疗蒽环类和(或)紫杉类均耐药转移性乳腺癌患者52例。吉西他滨1000mg/m2,静脉滴入,d1,d8;DDP25mg/m2,静脉滴入,d1～d3。21d为1个周期,至少用2个周期。本组患者治疗有效率为44.2%(23/52),中位生存时间11.0个月,中位疾病进展时间为5.3个月,1年生存率为42.3%。主要不良反应为胃肠道反应和骨髓抑制。Ⅲ～Ⅳ度呕吐发生率为28.9%(15/52)。Ⅲ～Ⅳ度中性粒细胞减少发生率为15.4%(8/52),Ⅲ～Ⅳ度血小板减少发生率为17.3%(9/52)。初步研究结果显示,吉西他滨联合DDP方案治疗蒽环类和(或)紫杉类均耐药的转移性乳腺癌疗效较好,毒副反应可耐受,是蒽环类及紫杉类耐药的转移性乳腺癌的有效选择。The objective of this study was to investigate the efficacy and toxicity of gemcitabine plus cisplatin （GP） regimen for anthracycline-and（or）taxane-resistant metastatic breast cancer（MBC）. A total of 52 breast cancer patients were treated by GP regimen. All had failures or relapse after previous treatment with anthracyclines and（or） taxanes. GP regimen： 1 000 mg/m^2 gemcitabine d1 , d8 and 25 mg/m^2 DDP infusion from d1 to d3. Treatments were repeated every 21 days and all patients received at least 2 cycles of chemotherapy. The overall response rate was 44.2%, the median survival time was 11.0 months, the median time to progression was 5.3 months and 1-year survival rate was 42.3%. The main side effects included gastrointestinal and hematologic toxicities. Grade3/4 toxicities included vomiting（28.9%,15/52）, neutropenia（15.4%,8/52） and thrombocytopenia（17.3%,9/52）. In conclusion, GP regimen is well effective for patients with anthracycline-and（or）taxane-resistant MBC. Drug related toxicities are tolerable. GP regimen is shown to be effective treatment options for pretreated MBC patients.

关 键 词：乳腺肿瘤/药物疗法 吉西他滨 顺铂 

分 类 号：R737.9[医药卫生—肿瘤]